Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502

BACKGROUND: While adjuvant chemotherapy is preferable for high-risk colon cancer, treatment duration is controversial. Oral uracil and tegafur (UFT)/leucovorin (LV) is widely used as a standard adjuvant chemotherapy for colon cancer in Japan. We conducted a phase III trial to investigate the optimal...

詳細記述

保存先:
書誌詳細
出版年:Ann Oncol
主要な著者: Sadahiro, S., Tsuchiya, T., Sasaki, K., Kondo, K., Katsumata, K., Nishimura, G., Kakeji, Y., Baba, H., Sato, S., Koda, K., Yamaguchi, Y., Morita, T., Matsuoka, J., Usuki, H., Hamada, C., Kodaira, S.
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2015
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4621030/
https://ncbi.nlm.nih.gov/pubmed/26347106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv358
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料